Research and Development Council of New Jersey

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Retrieved on: 
Monday, November 6, 2023
Auxilium, GCGR, Research and Development Council of New Jersey, Research, Medical college, IND, Glucagon-like peptide-1 receptor, Physician, GPR119, GSK plc, Development, Oxyntomodulin, Endo International, Ferring Pharmaceuticals, Johns Hopkins, NASH, Medicine, Biology, Ursinus College, OXM, Obstetrics, Tursi, Drexel University College of Medicine, GLP1R, Chemistry, Fatty liver disease, Bachelor of Science in Human Biology, Johns Hopkins Hospital, Investigational New Drug, Pharmaceutical industry, Gynaecology

Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.

Key Points: 
  • Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.
  • "James is a proven leader, with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," stated Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
  • As such, I look forward to working closely with the NeuroBo leadership team and my fellow Directors to maximize the potential for the Company's next generation pharmaceuticals to treat cardiometabolic diseases."
  • Previously, from April 2020 until January 2022, Dr. Tursi was Chief Scientific Officer U.S. for Ferring Pharmaceuticals.

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Retrieved on: 
Wednesday, June 28, 2023
Acumen, ABOS, LLP, University, OncoMed, Doctor of Philosophy, AbbVie, Stanford University, Epix Pharmaceuticals, ABBV, CSC, Cancer, Record, ASX, Babson College, PwC, IMU, Takeda Oncology, Proteostasis, Kineta, Molecular biology, Patient, CFO, Council, Therapy, Research and Development Council of New Jersey, NYSE, Biology, Pharmaceutical industry, Chimera, Biochemistry, Research

Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.

Key Points: 
  • Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.
  • Ms. Drapkin served as a member of Yumanity Therapeutics, Inc.’s board of directors since the completion of the merger of Proteostasis Therapeutics, Inc. and Yumanity, Inc. and previously served on the board of directors of Proteostasis.
  • Scott Dylla, Ph.D. is currently an entrepreneur, investor and advisor of early-stage biotech companies.
  • Dr. Dylla currently serves as the chairman of the board of Chimera Bioengineering and as a board member of 3D Bio Holdings LLC.

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Retrieved on: 
Monday, April 10, 2023
Amgen, ZymoGenetics, Biotechnology, Drug development, Executive, Senior, University, Seagen, Biogen, Binghamton University, University School, State university system, Drug, Janssen, Massachusetts General Hospital, Buffalo, Bristol Myers Squibb, Canagliflozin, Biology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Merck & Co., Organization, Research and development, Development, Patient, New York University Grossman School of Medicine, Robert Wood Johnson University Hospital, Internal medicine, University of Massachusetts Lowell, IND World's Fair Line, Genetic, Hospital, SANA, IND, Research and Development Council of New Jersey, Management, Pharmaceutical industry, Vertex, Endocrinology, Merck, Research

SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer. In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.

Key Points: 
  • In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.
  • In his career, he has participated in the development of over a dozen approved medicines across multiple therapeutic areas, including multiple blockbusters.
  • Dr. Meininger has over two decades of experience in drug development leadership, most recently at Vertex and previously at both Janssen and Merck.
  • He is currently the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company

Retrieved on: 
Wednesday, May 25, 2022
Department, 2013 articles about the Department of Justice investigations of reporters, Company, Research, President's Emergency Plan for AIDS Relief, Press release, Arrest, Sustainability Accounting Standards Board, NASDAQ, AIDS, US, Justice, Nature, Tuberculosis, H5 (US company), Lead, Board, The Global Fund to Fight AIDS, Tuberculosis and Malaria, List, Technology, Management, General counsel, Research and Development Council of New Jersey, HIV, SEC, GLOBE, Development, Annual report, LOS, Interim, Gilead Sciences, CEO, Online gambling, Pharmaceutical industry, Malaria

The Board of Directors of Enochian BioSciences Inc. met today and expressed unanimous and strong affirmation of the current position of the Company, the Management and the promising advancement of the Research and Development pipeline.

Key Points: 
  • The Board of Directors of Enochian BioSciences Inc. met today and expressed unanimous and strong affirmation of the current position of the Company, the Management and the promising advancement of the Research and Development pipeline.
  • The Board reviewed what is known and concluded without reservation that there is no link between the criminal charges and any actions of the Company.
  • Enochian BioSciences holds the exclusive rights to innovative, and potentially transformative, technology, said Gregg Alton, the Lead Independent Board Member and former Interim CEO and General Counsel of Gilead Sciences.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel

Retrieved on: 
Tuesday, January 4, 2022
Ernest Mario School of Pharmacy, Arnold & Porter, Sidley Austin, University, Acceleron Pharma, Development, Acquisition, Temple University School of Medicine, General counsel, Patient, Degenerative disease, Disc, Medical director, Temple University Hospital, Pharming, University of Michigan Law School, Hematologic disease, Research and Development Council of New Jersey, Regulatory affairs, Hope, Marion Merrell Dow, Public health, Internal medicine, Compliance, Merck, Arnold, Hematology, Safety, Board, Hoechst AG, Samuel, Board of directors, Multimedia, Saint Louis University College for Public Health and Social Justice, Leadership, Rutgers University, Pharmaceutical industry, Medical device, Celgene, Medicine, Research, Pharmacy, Acceleron

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jay T. Backstrom, M.D., M.P.H., to its Board of Directors, and the appointment of Rahul Khara, Pharm.D., J.D., as General Counsel. Dr. Backstrom was most recently Executive Vice President, Head of Research and Development at Acceleron Pharma and Dr. Khara was most recently Vice President, Legal and Chief Compliance Officer, also at Acceleron Pharma.

Key Points: 
  • Dr. Backstrom joins the Disc Medicine Board with over 30 years of experience in research and development.
  • Dr. Khara joins Disc Medicine from Acceleron where he served as Vice President, Legal and Chief Compliance Officer.
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.

PetHonesty Appoints Dr. Greg Reinhart as Vice President of Research and Development

Retrieved on: 
Thursday, November 11, 2021
Malnutrition, Ohio State University, Leadership, Education, Vestar Capital Partners, CEO, Knowledge, Doctor of Philosophy, Ohio, PETS, Research and Development Council of New Jersey, American College of Nutrition, Research and development, Communication, Development, General Mills, Parent, Allergy, Amazon, American College, Management, Bottled water

AUSTIN, Texas, Nov. 11, 2021 /PRNewswire/ -- PetHonesty, a trusted leader in premium pet health products and a portfolio company of Vestar Capital Partners, today announced the addition of Greg Reinhart, PhD, to its executive team as Vice President of Research and Development.

Key Points: 
  • AUSTIN, Texas, Nov. 11, 2021 /PRNewswire/ -- PetHonesty, a trusted leader in premium pet health products and a portfolio company of Vestar Capital Partners, today announced the addition of Greg Reinhart, PhD, to its executive team as Vice President of Research and Development.
  • Dr. Reinhart joins PetHonesty from General Mills, where he spent the last five years as Senior Vice President of Research and Development for the Blue Buffalo pet food brands.
  • His previous experience spans 17 years at the Iams Company and Procter & Gamble Pet Care, including serving seven years as the Vice President of Strategic Research and Communication.
  • He also held other positions of increasing responsibility in Research & Development within the company.

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

Retrieved on: 
Thursday, October 7, 2021
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, Twitter, Private Securities Litigation Reform Act, JAK2, Forward-looking statement, Diarrhea, Facebook, Inflammation, Health, Therapy, Lupus, Blood, BMY, Caregiver, Juno Therapeutics, Goal, IBD, LinkedIn, Safety, Ulcer, Bristol Myers Squibb, Trial of the century, HIV disease progression rates, Week, Annual report, Cytokine, UC, Instagram, U.S. Securities and Exchange Commission, Sores, Review, Rheumatology, JAK1, Ulcerative colitis, YouTube, JAK3, Mayo, Immune system, Psoriatic arthritis, Multiple sclerosis, Sumathi Best Television Current Reporting Award, Security (finance), Research and Development Council of New Jersey, Dermatology, NYSE, Inflammatory bowel disease, Solution, TYK2, Rectum, Patient, Science, Risk, Psoriasis, Gastroenterology, Research, JAK, Abdominal pain, IFN, Colon, Pharmaceutical industry, Medical imaging, LATTICE-UC, IM011-127, Deucravacitinib, Ulcerative Colitis, Bristol Myers Squibb, LATTICE-UC, IM011-127, DEUCRAVACITINIB, ULCERATIVE COLITIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb would like to thank the patients and investigators who were involved in the LATTICE-UC clinical trial.

Key Points: 
  • Bristol Myers Squibb would like to thank the patients and investigators who were involved in the LATTICE-UC clinical trial.
  • Bristol Myers Squibb continues to expect greater than $4 billion non-risk adjusted revenue target for deucravacitinib in 2029.
  • LATTICE-UC (IM011-024) is a Phase 2, randomized, placebo-controlled, multicenter study evaluating the safety and efficacy of deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
  • IM011-127 is a Phase 2, randomized, placebo-controlled, multicenter study evaluating the safety, efficacy and biomarker response of deucravacitinib in participants with moderate to severe ulcerative colitis (UC).

Hong Kong Investor Relations Association Announces Winners of the 7th IR Awards 2021

Retrieved on: 
Tuesday, September 14, 2021
Diamond, Friends, Program, IR, Research institute, Business, Financial Reporting Council, Award, Conference, Holding, Research, Seemabaddha, International Conference on Robotics and Automation, McIntire Investment Institute, Xtep, Industry, Financial services, COVID-19, HKEX, Public relations, Awareness, Research and Development Council of New Jersey, Cryptocurrency

Now in its seventh consecutive year, the Awards has been recognising and honouring investor relations ("IR") excellence and best practices among Hong Kong listed companies and IR professionals.

Key Points: 
  • Now in its seventh consecutive year, the Awards has been recognising and honouring investor relations ("IR") excellence and best practices among Hong Kong listed companies and IR professionals.
  • The 7th IR Awards 2021 enjoyed widespread support from listed companies and the investment sector.
  • The IR Pledge Program is designed to recognize Hong Kong listed companies with commitment to follow best practices in investor relations.
  • Strategic Public Relations Group is once again proud to be the Official Public Relations Partner and Diamond Sponsor of HKIRA IR Awards 2021.